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Abstract 
In recent years the safety of the yellow fever live vaccine 17D came under scrutiny. The focus 
was on serious adverse events after vaccinations that resemble a wild type infection with 
yellow fever and whose reasons are still not known. Also the exact mechanism of attenuation 
of the vaccine remains unknown to this day. In this context, the standards of safety and 
surveillance in vaccine production and administration have been discussed. Therein embodied 
was the demand for improved documentation of the derivation of the seed virus used for 
yellow fever vaccine production. So far, there was just a historical genealogy available that is 
based on source area and passage level. However, there is a need for a documentation based 
on molecular information to get better insights into the mechanisms of pathology. In this work 
we sequenced the whole genome of different passages of the YFV-17D strain used by Crucell 
Switzerland AG for vaccine production. Using all other publically available 17D full genome 
sequences we compared the sequence variance of all vaccine strains and oppose a 





































































Yellow fever is still one of the major health problems in Sub-Saharan Africa and big parts of 
South America. It is caused by the yellow fever virus (YFV), a positive-sense, single-stranded 
RNA virus belonging to the family Flaviviridae. YFV is transmitted between humans and 
non-human primates through several species of the mosquito genus Aedes [1].  
Despite the availability of the highly effective, live-attenuated vaccine 17D, there are still 
200.000 new cases with 30.000 deaths each year worldwide as estimated by the WHO [2]. 
The lethality of YFV induced pansystemic disease with fever, jaundice, renal failure and 
haemorrhage is up to 50%. Especially an increase of cases in the last years and the lasting 
absence of a potent treatment make the illness an important reemerging disease [3]. 
The 17D vaccine was developed in 1937 and over 540 million doses have been administered 
since then with good results [4]. During this period there have only been little changes in the 
production process and the genetic stability of the 17D strains is contributing to the safety of 
the vaccine [5]. The vaccine is absolutely contraindicated for children under 6 months and 
people that are immunocompromised, which is a significant problem in Africa where over 20 
million people are living with HIV (www.who.int). People over 60 years may be vaccinated 
in case of a medical need. Recently an increasing number of serious adverse events (SAE), 
occurring between two and 30 days after vaccination with YFV-17D, were reported [4, 5]. It 
can be distinguished between vaccine associated neurotropic disease (YEL-AND) and vaccine 
associated viscerotropic disease (YEL-AVD). YEL-AND causes encephalitis and occurs in 
0.19 – 0.8 cases per 100.000 vaccinations with a case fatality rate (CFR) of less than 5%. 
YEL-AVD resembles an infection with wild type YFV, occurs with a chance of 0.004 – 11.7 
per 100.000 and has a CFR of over 60% with a higher risk in women [4, 6]. The reasons for 
the occurrence of SAEs, as well as the mechanism of attenuation of the vaccine and its 




































































investigation of the possible influence of the YFV vaccine strain on the occurrence of the 
above mentioned serious adverse events. However, the benefit to risk ratio of YF vaccination 
is favorable in endemic areas. 
To date, the genealogy of YFV-17D is well documented but is based on historical information 
of passaging. From today’s perspective this kind of phylogeny is not up to date and should be 
revised with molecular information. Nonetheless, there is useful and important information 
such as passage level and worldwide distribution of the strains included in the historical flow 
sheet that need to be maintained [6].  
In this work we sequenced the whole genome (10862 bp) of different passages of Crucell’s 
YFV-17D strain, which was only sequenced partially until now [7]. This virus strain is used 
for vaccine production, but has not been licensed so far. As internal quality control we 
sequenced one vaccine lot of the vaccine Stamaril® by Sanofi Pasteur MSD that has already 
been published previously [8, 9]. Together with all other 17D full genome sequences 
available at the EMBL GenBank, we inferred a phylogenetic tree based on full genome 
sequences and compared it with the historical genealogy. Additionally we made a comparison 
of all sequence differences occurring between the vaccine strains for a better overview of 
mutations.  
 
2. Materials and Methods 
2.1 Sequenced virus strains 
RKI YFV vaccine, Crucell Switzerland AG (strain 17D-204, substrain 112/95, passage 238) 
(Accession-no.: JN628279); Flavimun working seed lot (WSL), Crucell Switzerland AG 
(strain 17D-204, substrain 112/95, passage 237) (Accession-no.: JN628280); TVX Flavimun 




































































(Accession-no.: JN628281); Stamaril® Yellow fever live vaccine, Sanofi Pasteur MSD (Ch.-
Nr.: Z6329-2) 
 
2.2 Sequences from EMBL GenBank 
The following full genome sequences were obtained from EMBL GenBank 
(http://www.ncbi.nlm.nih.gov/genbank/): 
YFV-17DD Brazil (DQ100292), YF-AVD2791-93F 04 from Spain (DQ118157), YFV 17D-
Tiantan China (FJ654700.1), YFV-17DD case#1 YEL-AVD Peru (GQ379162.1), YFV-17DD 
case#2 YEL-AVD Peru (GQ379163.1), YFV-17DD (U17066), YFV-17D-213 (U17067), 
YFV French neurotropic strain (U21055), YFV-17D-204_1 (USA) (X03700), YFV-17D-
204_2 (Pasteur) (X15062), YFV French viscerotropic strain (U21056), YFV Asibi 
(AY640589), Dengue 1 (NC_001477). 
 
2.3 Sequencing 
The cDNA synthesis from YFV RNA was performed using Superscript® III (InvitrogenTM) 
according to the manufacturers’ instructions. For the sequencing a minimum of 20 PCR 
products per virus strain were amplified with a set of YFV specific primers and Platinum®Taq 
polymerase (InvitrogenTM) [10]. PCR products were analyzed by agarose gel electrophoresis 
and purified by gel extraction (Invisorb® Spin DNA Extraction Kit, Stratec Molecular; 
QIAquick Gel Extraction Kit, Qiagen) before sequencing. The sequence reaction was 
performed according to Sanger on a 3500 xL Dx Genetic Analyzer (Applied BiosystemsTM). 
Reagents were used from the Big Dye® Terminator v3.1 Cycle Sequencing Kit (Applied 
BiosystemsTM). Sequence analysis was done with the help of the Lasergene® SeqMan Pro 





































































2.4 Sequence alignments and phylogenetic analyses 
We aligned the full genome nucleotide sequences of 16 YFV-strains using the muscle 
alignment tool from Geneious ProTM Version 5.3.4, Biomatters LTD. The genome of the 
Dengue virus serotype 1 (Dengue 1) was used as outgroup. 
The best fitting model of sequence evolution was determined using jModelTest 0.1 
(http://darwin.uvigo.es/software/jmodeltest.html) with three substitution schemes. Model 
selection was computed using the Akaike information criterion (AIC).  
Phylogenetic analyses were performed with Bayesian and Maximum likelihood (ML) 
methods to compare the support values of both mathematical methods.  
The Bayesian analyses were performed using MrBayes 3.1.2 
(http://mrbayes.csit.fsu.edu/index.php) [11] and consisted of two runs of four chains each. 
The GTR+G model of sequence evolution (General Time Reversible-model + Gamma-
distribution) was applied according to the results from jModelTest. The two runs were 
monitored for 10 million generations, sampled every 100th generation and the temperature 
coefficient of the chain-heating scheme was set to 0.1 to ensure sufficient chain-swapping. All 
runs reached stationarity within the calculation (average standard deviation of split 
frequencies <0.01). The program Tracer v1.5 (http://tree.bio.ed.ac.uk/software/tracer) was 
used to check for convergence of the model likelihood and parameters between the two runs 
and 10% of all trees were discarded as burn-in. A 50% majority-rule consensus tree was 
calculated in MrBayes 3.1.2. 
The ML analyses were carried out using the program Seaview 4.2.12 (http://pbil.univ-
lyon1.fr/software/seaview.html). Again, a GTR model was selected and further settings were 
left at the default. Two separate analyses were performed: one with 500 bootstraps and one 




































































The resulting Bayesian and ML consensus trees were visualised with the software Figtree 
v1.3.1 (http://tree.bio.ed.ac.uk/software/figtree) and rooted to midpoint. For visual clarity, the 
branches were transformed to a cladogram style.  
 
3. Results and Discussion 
For all newly sequenced yellow fever strains full genome sequences could be obtained. The 
sequences of the vaccine strains RKI YFV Vaccine, Flavimun® WSL and TVX Flavimun®-
product (provided by Crucell Switzerland AG) were identical.  
The sequencing of the Stamaril® vaccine yielded the same result as the internal sequencing by 
Sanofi Pasteur for the investigation of the stability of the vaccine [8]. Compared to the 
sequence of strain 17D-204 from Pasteur, we found four silent point mutations including one 
heterogeneity at nucleotide position 4054.  
The comparison of the nucleotide sequences of all 17D vaccines showed an overall homology 
of 99.2 % (Table 1). A total of 84 sequence differences are existent throughout the whole 
genome, whereof 29 have an effect on the protein level and are accumulating within the range 
of the E-protein. This comparison essentially supports the genetic stability of YF vaccine 
strains [5]. 
The phylogenetic trees inferred from the different analyses (Bayesian, ML) show a high 
overall similarity concerning topology and statistical support. Figure 1 shows the consensus 
tree of the Bayesian analysis. Node labels describe the appropriate posterior probability 
values (pp). Additionally, the support values for the ML analyses with 500 and 1000 
bootstraps (bs) are indicated in parentheses.   
In all analyses, the YF-17DD group administered in South America is clearly separated with 
high support (0.96pp, 97bs, 98bs) from the YF-17D group used in all other parts of the world 




































































only in the 17DD-group and of which 18 have an effect on the protein level. Only 12 of these 
nucleotide differences are common in all four 17DD-strains, leading to six amino acid 
changes (Table 1).   
Within the YF-17D group, the strains YFV-17D-204 deriving from USA and Pasteur form 
one well-supported clade (1pp, 89bs, 88bs). The strain 17D-204-Pasteur is the vaccine strain 
from the Institute Pasteur [9] whereas the strain 17D-204-USA derived from the American 
Type Culture Collection in passage number 234 and was not used for vaccine production [14]. 
The sequences of these strains have already been compared [9].  
Further on, the vaccine strains produced by Crucell Switzerland AG [7] together with the 
former vaccine strain from the Robert Koch-Institute (RKI, Germany) and the strain YFV-
17D-213 which is provided by the World Health Organization (WHO, Switzerland) [12, 15] 
form a clade which is especially strongly supported in the Bayesian analysis (0.99pp, 69bs, 
70bs). These two 17D subgroups are nested in a polytomy with the vaccine strain Stamaril® 
(France), an isolate from a YEL-AVD from Spain after vaccination with Stamaril® [16] and 
the Chinese vaccine strain YFV 17D-Tiantan. Regarding the historical genealogy of 17D-
passaging (Fig.2), YFV 17D-Tiantan was separated from the other strains at passage 229 and 
has with 13 nucleotide differences, leading to six amino acid changes, a lot of differences in 
its sequence compared to the other strains (Table 1) belonging to this polytomy. These 
differences do not have an influence on the placement of the strain in the phylogenies, 
because all sequence deviations occurring in YFV 17D-Tiantan are phylogenetically 
uninformative autapomorphies, meaning that they are unique characteristics in this strain. 
The sister group relationship of the wildtype strain Asibi towards the 17D and 17DD vaccine 
strains corresponds with the fact that 17D and 17DD arose from the Asibi strain through serial 
passaging [4, 17]. The YFV French viscerotropic strain is also a wild isolate and led to the 




































































was taken off the market due to severe side effects [17, 18]. These two strains form one clade 
that appears as sistergroup to Asibi in our analysis. However, this relationship is not 
statistically supported by any of the phylogenetic methods. 
 Compared to the historical genealogy, the phylogenetic tree based on full genome nucleotide 
sequences shows the same clustering of subgroups, with exception of the Chinese vaccine 
YFV 17D-Tiantan, which clusters in one polytomy with all other 17D vaccines in our 
analyses. Generally, the phylogenetic analysis reflects the historical way of 17D-distribution 
(Fig.1 and 2).  
 
During the last meeting of the Working Group on Technical Specifications for Manufacturing 
and Evaluating Yellow Fever Vaccines, several topics regarding vaccine safety, surveillance 
and production have been discussed [6]. One issue was the historical record of derivation of 
seed virus for the production of YF-vaccines. In Fig.2, the source and passage levels of the 
vaccine strains of all manufacturers are documented which is important for the surveillance of 
vaccine production. However, for vaccine safety as well as for the investigation of SAEs and 
vaccine attenuation, all master and working seeds should be sequenced and made publicly 
accessible. Up to now no link could be established between the occurrence of SAEs and YF-
vaccine genotypes. Indication exists that certain genetic predispositions of the vaccinees 
trigger the symptoms [19, 20]. Age is considered as risk factor.  
Previous studies that dealt with full genome analyses of yellow fever vaccine strains focused 
either on the comparison between wildtype and vaccine strains and by this on possible 
mutations leading to attenuation [12, 21, 22], or discussed the comparison of only few vaccine 
strains [9, 22, 23]. In this work we sequenced three more vaccine strains whose sequence has 
not been published until now and together with all other known full genomes of YFV-17D 




































































differences among the vaccines themselves and not in relation to the wildtype strains. 
Furthermore we open a new perspective of vaccine surveillance with a phylogenetic tree 
based on the full genome of all available YFV-vaccine strains, opposing the historical 
genealogy. More sequences are needed to assure the exact evolutionary history of YFV strains 
which is still unresolved, especially in the clade including the two 17D subgroups, the 
Stamaril® strain, the YEL-AVD isolate and the Chinese vaccine YFV 17D-Tiantan. 
Furthermore it would be useful for everyone who is working in this field to have access to 
more sequences with exact information on sequence differences as shown in Table 1.  
The sequence data of all YF 17D vaccine strains should also be used to confirm the identity 
and consistency of the vaccine production. Confirmed sequence identity might then also be 
used to replace the very laborious and difficult safety tests for the preparation of the 17D 
working seed, i.e. intracerebral injection of working seed lots into monkeys followed by an 
extensive histological examination which is still mandatory for vaccine production according 
to WHO recommendations [16]. A substitution with the new and easy sequencing techniques 
as reliable tool for vaccine characterisation should be considered and should also lead to 
corresponding adaptations of the safety regulations as part of the vaccine production in the 





































































Fig. 1: Majority-rule consensus tree of the Bayesian analysis with 10 million generations based on full genome 
nucleotide sequences of the Yellow fever virus 17D vaccine strains. Posterior probability values are given on the 
right side of the related node. Bootstrap values of the ML analysis with 500 and 1000 bootstraps are displayed in 






































































Fig. 2: YFV-17D genealogy based on historical data of passaging and transfer (modified from WHO [15]). 
Newly sequenced vaccine strains are indicated with an asterisk *; sequences derived from Genbank are 






































































Table 1:  Sequence differences between all available YFV vaccine strains. Divergent nucleotides are highlighted 









































































[1] Gould EA, Solomon T. Pathogenic flaviviruses. Lancet 2008 Feb 9;371(9611):500-9. 
[2] Niedrig M, Böthe M. Gelbfieber - Eine zunehmende Gefahr. Die Medizinische Welt 
2008;59(7/8):257-60. 
[3] Monath TP. Treatment of yellow fever. Antiviral research 2008 Apr;78(1):116-24. 
[4] Barrett AD, Teuwen DE. Yellow fever vaccine - how does it work and why do rare cases of 
serious adverse events take place? Current opinion in immunology 2009 Jun;21(3):308-13. 
[5] Barrett AD, Monath TP, Barban V, Niedrig M, Teuwen DE. 17D yellow fever vaccines: new 
insights. A report of a workshop held during the World Congress on medicine and health in the 
tropics, Marseille, France, Monday 12 September 2005. Vaccine 2007 Apr 12;25(15):2758-65. 
[6] Ferguson M, Shin J, Knezevic I, Minor P, Barrett A. WHO Working Group on Technical 
Specifications for Manufacture and Evaluation of Yellow Fever Vaccines, Geneva, Switzerland, 13-14 
May 2009. Vaccine 2010 Dec 6;28(52):8236-45. 
[7] Pfister M, Kursteiner O, Hilfiker H, Favre D, Durrer P, Ennaji A, et al. Immunogenicity and 
safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. The 
American journal of tropical medicine and hygiene 2005 Mar;72(3):339-46. 
[8] Barban V, Girerd Y, Aguirre M, Gulia S, Petiard F, Riou P, et al. High stability of yellow fever 
17D-204 vaccine: a 12-year restrospective analysis of large-scale production. Vaccine 2007 Apr 
12;25(15):2941-50. 
[9] Dupuy A, Despres P, Cahour A, Girard M, Bouloy M. Nucleotide sequence comparison of the 
genome of two 17D-204 yellow fever vaccines. Nucleic acids research 1989 May 25;17(10):3989. 
[10] Bae H-G. "Analyse der Immunantwort nach Infektion mit Gelbfieberviren". Berlin: Freie 
Universität Berlin; 2006. 
[11] Ronquist F, Huelsenbeck JP. MrBayes 3: Bayesian phylogenetic inference under mixed 
models. Bioinformatics 2003 Aug 12;19(12):1572-4. 
[12] dos Santos CN, Post PR, Carvalho R, Ferreira, II, Rice CM, Galler R. Complete nucleotide 
sequence of yellow fever virus vaccine strains 17DD and 17D-213. Virus research 1995 Jan;35(1):35-
41. 
[13] Whittembury A, Ramirez G, Hernandez H, Ropero AM, Waterman S, Ticona M, et al. 
Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 2009 Oct 9;27(43):5974-81. 
[14] Rice CM, Lenches EM, Eddy SR, Shin SJ, Sheets RL, Strauss JH. Nucleotide sequence of yellow 
fever virus: implications for flavivirus gene expression and evolution. Science 1985 Aug 
23;229(4715):726-33. 
[15] WHO/BS/10.2131. Expert Committee on Biological Standardization: Recommendations to 
Assure the Quality, Safety and Efficacy of Live Attenuated Yellow Fever Vaccines; Proposed 
replacement of: TRS 872, Annex 2 and Amendment to TRS 872, Annex 2, TRS (in press). (ECSB 2008). 
[16] Doblas A, Domingo C, Bae HG, Bohórquez CL, de Ory F, Niedrig M, et al. Yellow fever vaccine-
associated viscerotropic disease and death in Spain. Journal of Clinical Virology 2006;36(2):156-8. 
[17] Frierson JG. The yellow fever vaccine: a history. The Yale journal of biology and medicine 
2010 Jun;83(2):77-85. 
[18] Barrett ADT. Vaccines for biodefense and emerging and neglected diseases, 2009. 
[19] Monath TP, Cetron MS, McCarthy K, Nichols R, Archambault WT, Weld L, et al. Yellow fever 
17D vaccine safety and immunogenicity in the elderly. Human vaccines 2005 Sep-Oct;1(5):207-14. 
[20] Pulendran B, Miller J, Querec TD, Akondy R, Moseley N, Laur O, et al. Case of yellow fever 
vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune 





































































[21] Hahn CS, Dalrymple JM, Strauss JH, Rice CM. Comparison of the virulent Asibi strain of yellow 
fever virus with the 17D vaccine strain derived from it. Proceedings of the National Academy of 
Sciences of the United States of America 1987 Apr;84(7):2019-23. 
[22] Wang E, Ryman KD, Jennings AD, Wood DJ, Taffs F, Minor PD, et al. Comparison of the 
genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative 
French neurotropic vaccine. The Journal of general virology 1995 Nov;76 ( Pt 11):2749-55. 
[23] Galler R, Post PR, Santos CN, Ferreira, II. Genetic variability among yellow fever virus 17D 
substrains. Vaccine 1998 May-Jun;16(9-10):1024-8. 
 
 
Nucleotideposition 142 237 370 490 643 883 1003 1140 1150 1431 1436 1437 1491 1558 1692 1946 2003 2110 2219 2220 2356 2677 3470
Stamaril® YF-vaccine A C C G A G T T G A G A T C C T A G A C T C A
YF-AVD2791-93F 04 from spain A C C G A G T T G A G A T C C T A G A C T C A
Crucell® TVX Flavimun A C C G A G T T G C G A T C C T A G A C T C A
Crucell® Flavimun WSL A C C G A G T T G C G A T C C T A G A C T C A
RKI YFV vaccine A C C G A G T T G C G A T C C T A G A C T C A
YFV-17D-213 A C C G A G T T G C G A T C C T A G A C T C A
YFV-17D-204_2 A C C G A G T T G A G A T C C T A G A C T C A
YFV-17D-204_1 A C C G A G T T G A G A T C C T A G A C T C A
YFV 17D-Tiantan China G T C A A G T T A A G A C C T T A G A C T C G
YFV-17DD Brazil A C C G A A T C G A G A T C C C G G A C C C A
YFV-17DD A C T G G A T C G A A G T A C C A A G T T C A
YFV-17DD case#1 YEL-AVD Peru A C T G G A T C G A A G T A C C A G G T C T A
YFV-17DD case#2 YEL-AVD Peru A C T G G A Y C G A A G T A C C A G G T C T A
Nucleotideposition 3599 3637 3668 4013 4054 4204 4222 4523 4559 4612 4804 4873 4921 4942 4948 4957 4972 5115 5123 5153 5161 5225 5362
Stamaril® YF-vaccine T C C T Y C G C G C T G G A C C G A C G T A C
YF-AVD2791-93F 04 from spain T C C T T C G C G C T G G A C C G A C G T A C
Crucell® TVX Flavimun T C C T T C G C G C T G G A C C G A C G T A T
Crucell® Flavimun WSL T C C T T C G C G C T G G A C C G A C G T A T
RKI YFV vaccine T C C T T C G C G C T G G A C C G A C G T A T
YFV-17D-213 T C C T T C G C G C T G G A C C G A C G T A T
YFV-17D-204_2 T C C T T C G C G C T G G A C C G A C G T A C
YFV-17D-204_1 T C C T T C G C G C T G G A C C G A C G T A C
YFV 17D-Tiantan China T C T T T C G C A C T G G A C C G A C G T A C
YFV-17DD Brazil T C C C C C A C G T C T G A C C G A T A C A C
YFV-17DD C T C C C T G C G T T T G G C T A G C A T C A
YFV-17DD case#1 YEL-AVD Peru C T C C C T G Y G T T T G G C T A G C A T C C
YFV-17DD case#2 YEL-AVD Peru C T C C C T G Y G T T T A G Y T A G C A T C C
Nucleotideposition 5393 5641 6070 6280 6418 6514 6529 6625 6673 6758 6947 7319 7496 7497 7571 7701 7975 8029 8099 8808 9397 9522 9523
Stamaril® YF-vaccine T G C C T T T A T A C A T T A G C T G A A T G
YF-AVD2791-93F 04 from spain T G C C C T T A T A C A T T A G C T G A A T G
Crucell® TVX Flavimun T G C C T T T A T A C A C T A G C T G A A T G
Crucell® Flavimun WSL T G C C T T T A T A C A C T A G C T G A A T G
RKI YFV vaccine T G C C T T T A T A C A C T A G C T G A A T G
YFV-17D-213 T G C C T T T C T A C A T C A G C T G A A T G
YFV-17D-204_2 T A C C T T T A T A C A T T A G C T G A A T G
YFV-17D-204_1 T A C C T T C A T G C G T T A G C T G A A T G
YFV 17D-Tiantan China T G C G T T T A T A C A T T A G C T G A A T G
YFV-17DD Brazil C G T C T T T A T A T A T T C A C T A G A A T
YFV-17DD T G T C T C T C T A C A T T C A T C G G G T G
YFV-17DD case#1 YEL-AVD Peru T G T C T C T C Y A C A T T C A T C G G G T G
YFV-17DD case#2 YEL-AVD Peru T G T C T C T C Y A C A T T C A T C G G G T G
Nucleotideposition 9605 9783 9988 10144 10174 10243 10291 10367 10454 10550 10675 10722 10815 10847 10860
Stamaril® YF-vaccine A A C A A G C C A C A G G C A
YF-AVD2791-93F 04 from spain A A C A A G C C A C A G G C A
Crucell® TVX Flavimun A A C A A G C C A C A G G C A
Crucell® Flavimun WSL A A C A A G C C A C A G G C A
RKI YFV vaccine A A C A A G C C A C A G G C A
YFV-17D-213 A A C A A A C C A C A G G C A
YFV-17D-204_2 A A C A A A C C A C A A G C A
YFV-17D-204_1 G A C A A A C C G C A G G C A
YFV 17D-Tiantan China A A C G A G C C A C A G A C T
YFV-17DD Brazil A G C A A G C T A T A G G C A
YFV-17DD A A C A A A C C A T A G G C A
YFV-17DD case#1 YEL-AVD Peru A A C A A G C T A T A G G A A
YFV-17DD case#2 YEL-AVD Peru A A Y A R G Y T A T R G G A A
NS5
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